Warning: Attempt to read property "ID" on null in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/assets/functions/cleanup.php on line 74

Warning: Attempt to read property "ID" on null in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/assets/functions/cleanup.php on line 74
{"version":"1.0","provider_name":"Celon Pharma","provider_url":"https:\/\/celonpharma.com\/en\/","title":"Celon Pharma na \u00a0Kongresie\u00a0ECNP\u00a0 - Celon Pharma","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"BB18eWh2u6\"><a href=\"https:\/\/celonpharma.com\/en\/celon-pharma-na-kongresie-ecnp\/\">Celon Pharma na \u00a0Kongresie\u00a0ECNP\u00a0<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/celonpharma.com\/en\/celon-pharma-na-kongresie-ecnp\/embed\/#?secret=BB18eWh2u6\" width=\"600\" height=\"338\" title=\"&#8220;Celon Pharma na \u00a0Kongresie\u00a0ECNP\u00a0&#8221; &#8212; Celon Pharma\" data-secret=\"BB18eWh2u6\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/celonpharma.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Celon Pharma na &nbsp;Kongresie&nbsp;ECNP&nbsp;(European College of Neuropsychopharmacology). W trakcie konferencji zostan\u0105 zaprezentowane wyniki bada\u0144 przedklinicznych inhibitora PDE10a w obszarze dyskinez polewodopowych. Sesj\u0119 posterow\u0105 poprowadzi dr Miko\u0142aj Mat\u0142oka, a tytu\u0142 posteru to:&nbsp; &#8220;CPL500036 \u2013 a novel inhibitor of phosphodiesterase 10A \u2013 attenuates the development of L-DOPA-induced dyskinesias in 6-OHDA lesioned rats.&#8221;&nbsp;Prezentacja odb\u0119dzie si\u0119 we wtorek 18&nbsp;pa\u017adziernika&nbsp;13:00Read more &raquo;","thumbnail_url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/CELON_LI_202210_43-1024x535.png"}